Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Lederman

Showing results (251-260 of 303) with videos related to

Pageof 31
Sort By:
The Journal of Infectious Diseases|December 16, 2003
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson, Michael M Lederman, John Spritzler, et al.
Plos Medicine|August 17, 2010
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialRajesh T Gandhi, Lu Zheng, Ronald J Bosch, et al.
Cell Reports. Medicine|September 25, 2024
Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIVTimothy J Henrich, Ronald J Bosch, Catherine Godfrey, et al.
Pathogens & Immunity|November 4, 2017
Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIVMartha A Belury, Emily Bowman, Janelle Gabriel, et al.
AIDS Research and Human Retroviruses|June 25, 2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha, Hernan Valdez, Rebecca S Gelman, et al.
The Journal of Infectious Diseases|September 16, 2011
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cellsMichael M Lederman, Leonard Calabrese, Nicholas T Funderburg, et al.
The Journal of Infectious Diseases|July 1, 2020
Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic ControlEva Poveda, Andrés Tabernilla, Wendy Fitzgerald, et al.
Plos Pathogens|June 5, 2010
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite controlAdam R Hersperger, Florencia Pereyra, Martha Nason, et al.
The Journal of Infectious Diseases|February 6, 2018
Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy AloneNetanya S Utay, Douglas W Kitch, Eunice Yeh, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2020
<i>In Vitro</i> Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression ProfilesEmily R Bowman, Cheryl Cameron, Brian Richardson, et al.
Pageof 31

Showing results (251-260 of 303) with videos related to

Sort By:
Pageof 31
The Journal of Infectious Diseases|December 16, 2003
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson, Michael M Lederman, John Spritzler, et al.
Plos Medicine|August 17, 2010
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialRajesh T Gandhi, Lu Zheng, Ronald J Bosch, et al.
Cell Reports. Medicine|September 25, 2024
Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIVTimothy J Henrich, Ronald J Bosch, Catherine Godfrey, et al.
Pathogens & Immunity|November 4, 2017
Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIVMartha A Belury, Emily Bowman, Janelle Gabriel, et al.
AIDS Research and Human Retroviruses|June 25, 2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha, Hernan Valdez, Rebecca S Gelman, et al.
The Journal of Infectious Diseases|September 16, 2011
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cellsMichael M Lederman, Leonard Calabrese, Nicholas T Funderburg, et al.
The Journal of Infectious Diseases|July 1, 2020
Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic ControlEva Poveda, Andrés Tabernilla, Wendy Fitzgerald, et al.
Plos Pathogens|June 5, 2010
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite controlAdam R Hersperger, Florencia Pereyra, Martha Nason, et al.
The Journal of Infectious Diseases|February 6, 2018
Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy AloneNetanya S Utay, Douglas W Kitch, Eunice Yeh, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2020
<i>In Vitro</i> Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression ProfilesEmily R Bowman, Cheryl Cameron, Brian Richardson, et al.
Pageof 31